Radioiodine Refractory Differentiated Thyroid Carcinoma

A key opinion leader discusses the evolving treatment landscape for radioiodine refractory differentiated thyroid carcinoma, with special consideration of the phase 3 SELECT trial.

Related Videos
Aaron Gerds, MD, MS, an expert on myelofibrosis
Aaron Gerds, MD, MS, an expert on myelofibrosis
Aaron Gerds, MD, MS, an expert on myelofibrosis
Aaron Gerds, MD, MS, an expert on myelofibrosis
Aaron Gerds, MD, MS, an expert on myelofibrosis
Aaron Gerds, MD, MS, an expert on myelofibrosis
Aaron Gerds, MD, MS, an expert on myelofibrosis
Stephen Oh, MD, PhD, an expert on myelofibrosis
Stephen Oh, MD, PhD, an expert on myelofibrosis
Stephen Oh, MD, PhD, an expert on myelofibrosis